Understanding the microbiology and treatment outcomes of bronchiectasis exacerbations in Hong Kong
Microbiology and Treatment Outcome of Acute Exacerbation of Bronchiectasis in Hong Kong: a Prospective Study
This study looks at the germs causing flare-ups of bronchiectasis in Hong Kong to see how common a specific infection is and how it affects treatment outcomes for patients in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pamela Youde Nethersole Eastern Hospital Academic / other |
| Locations | 1 site (Hong Kong, Other) |
| Trial ID | NCT05112055 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the microbiology of acute exacerbations of bronchiectasis (AEB) in Hong Kong, focusing on the prevalence of pseudomonas aeruginosa infections. It will utilize both traditional culture methods and advanced molecular multiplex techniques to enhance pathogen detection. Additionally, the study will identify factors associated with PA infection and evaluate the management and treatment outcomes for patients hospitalized with AEB. The findings are expected to inform better antibiotic use and improve patient care.
Who should consider this trial
Good fit: Ideal candidates include adults with a clinical diagnosis of acute exacerbation of bronchiectasis who are admitted to the hospital.
Not a fit: Patients under 18 years old, those unable to provide informed consent, or those with bronchiectasis due to cystic fibrosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for patients experiencing acute exacerbations of bronchiectasis.
How similar studies have performed: While there is limited local data on this specific topic, similar studies in other regions have successfully identified microbial patterns in bronchiectasis exacerbations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Patients admitted to participating hospital with a clinical diagnosis of acute exacerbation of bronchiectasis (AEB), defined as a change in bronchiectasis treatment associated with deterioration in three or more of the following key symptoms for at least 48 hours: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; or haemoptysis. 2. Patients with an established diagnosis of bronchiectasis, defined as the presence of cough, shortness of breath, chronic sputum production, recurrent respiratory infection, or a combination thereof with CT thorax scan confirmation of the presence of bronchiectasis indicated by a bronchoarterial ratio of \> 1, lack of tapering, airway visibility within 1 cm of the pleural surface, or a combination thereof. Exclusion criteria 1. Patients unable to provide informed consent 2. Age \< 18 years 3. Pregnancy 4. Bronchiectasis due to known cystic fibrosis 5. Bronchiectasis is not the main or co-dominant respiratory disease 6. Traction bronchiectasis due to interstitial lung disease 7. Prior lung transplantation for bronchiectasis
Where this trial is running
Hong Kong, Other
- Charles Wong — Hong Kong, Other, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Charles Wong — Pamela Youde Nethersole Eastern Hospital
- Study coordinator: Charles Wong
- Email: wc679@ha.org.hk
- Phone: 25956111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.